15 results about "ATOPICLAIR" patented technology

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

The present invention is related to novel methods for identifying a population of subjects that are at risk for developing of atopic allergic diseases, and to the prevention of these allergic diseases.

The present invention relates generally to maqui berry for use in the treatment or prevention of skin diseases, wherein maqui berry may be the primary natural active ingredient. Particular embodiments as disclosed herein find application in, inter alia, the prophylaxis and the treatment of skin diseases, in particular, dermatitis, atopic dermatitis (neurodermatitis), dermatitis solaris, eczema, hand eczema, lichen planus, lupus erythematosus, psoriasis, urticaria, itching, scabies, age spot, freckles and dry / atopic skin of humans. In particular, the present invention relates to the use of maqui berry extract in the manufacture of a medicament or dietary supplement for use in treating or preventing said skin diseases or defects.

The present invention relates to a paste composition, a biodegradable injectable paste, and a method for producing the same. According to the present invention, the paste composition may offer the convenience of being applied to the application site using one syringe without the need to mix using two syringes immediately before use, by providing a crosslinked hydrogel as a paste phase, as well as biocompatibility, tackiness, and the balance between viscosity and elasticity, and thus is suitable for use in applications, including hemostatic agents, bone fillers, wound dressings, drug carriers, tissue repair materials, skin soothing agents, moisturizing agents, anti-inflammatory agents, and anti-atopic agents.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

In some embodiments, a composition comprising an effective amount of Bifidobacterium breve, Bifidobacterium bifidum, and Lactobacillus salivarius is provided. In some embodiments, the use of the composition in the prevention or treatment of atopic eczema in a subject is provided. In some embodiments, there is provided a method of preventing or treating atopic eczema in a subject, the method comprising the step of administering to the subject an effective amount of the composition. In some embodiments, there is provided a kit comprising: a composition of any one of the examples herein; and at least one container selected from the group consisting of capsules, pouches, packets, sachets, bottles, and blister packages. Other exemplary embodiments are described herein. In certain embodiments, the compositions are safe to use and effective to prevent or treat atopic eczema in a subject, especially an adult subject.

The present invention relates to interleukin 18 (IL-18) antibody therapies, low dose formulations of anti-IL-18 neutralizing antibodies, and the use of such formulations for the treatment of IL-18 related diseases by subcutaneous administration. The invention further relates to the use of said anti-IL-18 neutralizing antibody low-dose formulations in the treatment of e.g., adult pathogenic Stetill Disease (AOSD) or systemic pathogenic juvenile idiopathic arthritis (SoJIA, SoJIA, SoJIB, SoJIA, SoJIB, SoJIA, SoJIA, SoJIA, SoJIA, the present invention relates to the use thereof in Still disease such as Still disease (e.g., juvenile Still disease), atopic eczema or atopic dermatitis (AD), inflammatory bowel disease such as ulcerative colitis (UC) and Crohn's disease (CD), and eosinophilic esophagitis (EoE).

The present invention relates to a dermatological or dermatocosmetic composition in the form of a paraffin-free emulsion, which is particularly suitable for the treatment of inflammatory skin diseases, in particular sensitive or atopic skin. The composition comprises an aqueous phase comprising at least one emollient selected from polyols and an oily phase comprising an oily emollient system comprising at least 70% by weight of safflower oil and a second oily emollient.

The present invention relates to a dermatological or cosmetic skin composition in the form of a paraffin-free emulsion, particularly suitable for the treatment of inflammatory skin diseases, especially sensitive or atopic skin. The composition comprises an aqueous phase containing at least one emollient selected from polyols, and an oil phase containing an oily emollient system comprising at least 70% by weight of safflower oil and a second oily emollient.

Provided herein are compounds of Formula I which are thymic stromal lymphopoietin (TSLP) or thymic stromal lymphopoietin receptor (TSLPR) inhibitory compounds, capable of disrupting the protein-protein interaction between TSLP and TSLPR. Compounds of Formula I and compositions thereof modulate activity or inhibit TSLP and TSLPR binding, and are useful for downregulating atopy-relevant pro-inflammatory cytokines. In particular, compounds of Formula I as described herein are useful in the treatment of skin disease, allergic asthma, allergic rhinitis, drug allergies, and food allergies. Furthermore, the compounds described herein are absorbed by the skin. (I)

The invention discloses an application of a Momelotinb (CYT387) ointment in preparation of a medicine for treating atopic dermatitis and a preparation method of the Momelotinb (CYT387) ointment. The appearance, the viscosity, the irritation, the stability and the like of the Momelotinb (CYT387) ointment prepared by the preparation method disclosed by the invention can meet the requirements of applying on skin; the Momelotinb (CYT387) ointment has the advantages that the Momelotinb (CYT387) ointment is more easily percutaneously permeated into epidermis and dermis tissues in pharmacodynamic property, and main effective components are distributed on the superficial layer of skin, so that the Momelotinb (CYT387) ointment can be favorably applied to treatment of Compared with commercially available tacrolimus, the drug effect of the Momelotinb (CYT387) ointment is similar, however, the Momelotinb (CYT387) ointment has stronger tolerance, and compared with other hormone ointment, the Momelotinb (CYT387) ointment is accurate in target spot and more remarkable in curative effect on AD (Alzheimer's disease). Clinically developed as a substitute medicine of tacrolimus or other hormones for treating atopic dermatitis, the compound has great practical application value, and can be used as a novel and effective external preparation for treating atopic dermatitis.

A cosmetic composition for alleviating skin itching and improving atopic symptoms, according to the present invention, comprises a eutectic mixture of glutamine and linoleic acid, and exhibits the following effects: increasing the skin penetration of glutamine and enhancing skin barrier function, thereby substantially alleviating atopic symptoms including itching; improving the water solubility of linoleic acid, thereby enhancing antioxidant activity and skin protection effects; providing synergistically enhanced effects on alleviating atopic symptoms including itching and enhancing skin protection, as compared to the use of glutamine or linoleic acid alone, without adverse effects; and achieving enhanced effects in alleviating atopic symptoms including itching and improving skin protection, without adverse effects associated with surfactants and oils.

A novel strain, Lactobacillus paracasei ATG-E1 (Accession No. KCTC 14245BP), and a composition containing the same for preventing or treating respiratory diseases which are caused by fine particulate matter. The Lactobacillus paracasei ATG-E1 strain reduces the number of immune cells bronchoalveolar and lung tissues and inhibits the expression of inflammatory cytokines such as interleukin-17A (IL-17A), tumor necrosis factor-α (TNF-α), macrophage inflammatory protein 2 (MIP2), C-X-C motif chemokine ligand 1 (CXCL-1), macrophage inflammatory protein-α (MIP-1α) or interleukin-6 (IL-6). Therefore, the Lactobacillus paracasei ATG-E1 strain can be used for a treatment or health functional food for various respiratory diseases such as acute and chronic bronchitis, catarrhal bronchitis, bronchitis obliterans, inflammatory bronchitis, bronchial asthma, atopic asthma, non-atopic asthma, atopic IgE-mediated asthma, allergic asthma, non-allergic asthma, chronic bronchoconstriction, acute bronchoconstriction, chronic obstructive pulmonary disease, bronchial adenoma, pulmonary tuberculosis, emphysema, lung abscess, pulmonary fibrosis, lung cancer, airway cancer, bronchoalveolar cancer, and bronchial cancer.

The present invention relates to a composition for preventing, alleviating, or treating atopic march and, more particularly, to a composition for preventing, alleviating, or treating atopic march, the composition containing, as active ingredients, a Lactococcus lactis subsp. lactis strain and a gardenia jasminoides fruit extract. The composition may be applied to atopic march-related diseases including food allergies, dermatitis, rhinitis, conjunctivitis, and asthma. The composition according to the present invention may, in an animal model of atopic march, alleviate atopic dermatitis-like skin lesions, regulate Th2-related cytokines and allergy-related antibodies, increase the expression of intestinal mucosal barrier-related factors, inhibit airway hypersensitivity and lung inflammation, and contribute to the recovery of immune homeostasis at the level of the intestinal-lung axis by changing the composition and function of intestinal and BALF microbial groups, and thus may be particularly useful for inhibiting the progression and alleviating symptoms of atopic march.